40th week of 2017 patent applcation highlights part 29 |
Patent application number | Title | Published |
20170283419 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS - The present invention relates to purine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections. | 2017-10-05 |
20170283420 | INDOLINE ANALOGS AND USES THEREOF - Indoline derivative compounds that act as EWS-FLI1 transcription factor inhibitors are provided. Also provided are pharmaceutical compositions of the indoline derivatives, methods of synthesizing the same, methods of treating using same, and assays for identifying the inhibitors of EWS-FLI1 oncoprotein. | 2017-10-05 |
20170283421 | SUBSTITUTED N-(PYRROLIDINE-3-YL)-7H-PYRROLO[2,3-D]PYRIMIDINE-4-AMINE AS JANUS KINASE INHIBITOR - A novel substituted N-(pyrrolidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine and a use thereof as a Janus kinase (JAK) inhibitor are provided. | 2017-10-05 |
20170283422 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS - The present invention relates to novel pyrimido-diazepinone compounds, methods of modulating protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), LRKK2, EphA2, polo kinase 1, 2, 3, or 4, Ack1, Ack2, Abl, DCAMKL1, ABL1, Abl mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4, PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Abl, GAK, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkC, and the use of such compounds in the treatment of various diseases, disorders or conditions. | 2017-10-05 |
20170283423 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR - Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described, wherein the compounds have formula Ia: | 2017-10-05 |
20170283424 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS - A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R | 2017-10-05 |
20170283425 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF - The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin-related disorders. | 2017-10-05 |
20170283426 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF - The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin-related disorders. | 2017-10-05 |
20170283427 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF - The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin-related disorders. | 2017-10-05 |
20170283428 | METHOD FOR EXTRACTING HIGH-PURITY ASARININ BY SUPERCRITICAL CARBON DIOXIDE EXTRACTION METHOD AND USE THEREOF - The invention discloses a method for extracting high-purity asarinin and use thereof. The method comprises: putting crude | 2017-10-05 |
20170283429 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS - Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV). | 2017-10-05 |
20170283430 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE - The present disclosure is directed to compounds of Formula (I) and methods of their use and preparation, as well as compositions comprising compounds of Formula (I). | 2017-10-05 |
20170283431 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE - The present disclosure is directed to compounds of formula I′ and methods of their use and preparation, as well as compositions comprising compounds of formula I′. | 2017-10-05 |
20170283432 | DERIVATIVES OF MACROCYCLIC N-ARYL-TRICYCLOPYRIMIDINE-2-AMINE POLYETHERS AS INHIBITORS OF FTL3 AND JAK - The present invention relates to a compound with the following formula (I): (I) or a salt and/or a pharmaceutically acceptable solvate thereof, in particular for use as a drug, in particular in the treatment of cancer, as well as to the pharmaceutical compositions that contain same and to the methods for preparing same. | 2017-10-05 |
20170283433 | PHARMACEUTICAL FORMULATIONS CONTAINING 3-(4-CINNAMYL-L-PIPERAZINYL) AMINO DERIVATIVES OF 3-FORMYLRIFAMYCIN SV AND 3-FORMYLRIFAMYCIN S AND A PROCESS OF THEIR PREPARATION - The present invention related to a process of preparation of pharmaceutically acceptable formulations containing as active substance 3-(4-cinnamy-1-piperazinyl)-amino derivatives of 3-formylrifamycine SV and 3-formylrifamycine S, which possess high activity against Gram-positive and Gram-negative microorganisms, as well as against tuberculous micobacteria (including atypical and rifamycin resistant), and to a method for the preparation of 3-(4-cinnamyl-1-piperazinyl)-amino derivatives of 3-formylrifamycine SV and 3-formylrifamycine S. The method for the preparation of pharmaceutical compositions is readily feasible, and does not require special equipment for its implementation. The process for preparing the compounds is characterized by high yield and purity, using an environmental clean solvent—ethanol and water in the preparation and isolation of substances, and the absence of residual organic solvents in the final product. | 2017-10-05 |
20170283434 | NK1 ANTAGONISTS | 2017-10-05 |
20170283435 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS - Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R | 2017-10-05 |
20170283436 | PROBES FOR IMAGING HUNTINGTIN PROTEIN - Provided are imaging agents comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use. | 2017-10-05 |
20170283437 | Inhibitors of UDP-Galactopyranose Mutase - Compounds and salts thereof which inhibit microbial growth or attenuate the virulence of pathogenic microorganisms and which inhibit UDP-galactopyranose mutase (UGM). Compounds of the invention include triazolothiadiazines, particularly 3, 6, 7-substituted-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines, and 4-(1H-pyrrol-3-yl) thiazoles, particularly 4-(1,2,5-substituted-1H-pyrrol-3-yl)-2-substituted thiazoles, and salts thereof. Methods for inhibiting growth or attenuating virulence of microbial pathogens including mycobacterium, for example, M. tuberculosis and M. smegmatis and Klebsiella, for example, Klebsiella pneumoniae. Methods for inhibiting eukaryotic human and animal pathogens, and fungi and nematodes in particular. Methods for treatment of infections by prokaryotic and eukaryotic pathogens employing compounds of the invention. | 2017-10-05 |
20170283438 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS - Disclosed are compounds of Formula (I) | 2017-10-05 |
20170283439 | PROBES FOR IMAGING HUNTINGTIN PROTEIN - Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use. | 2017-10-05 |
20170283440 | CARM1 INHIBITORS AND USES THEREOF - Provided herein are compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, R | 2017-10-05 |
20170283441 | PRODUCTION METHOD FOR 2-FLUORO-4-BORONO-L-PHENYLALANINE, AND PRECURSOR OF 2-FLUORO-4-BORONO-L-PHENYLALANINE - The present invention involves preparing compounds represented by the following formula: | 2017-10-05 |
20170283442 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules - The present application discloses compositions and methods of synthesis and use of | 2017-10-05 |
20170283443 | FLUOROSILICON NITRILE COMPOUNDS - Novel fluorosilicon nitrile compounds, and methods of preparing them, are described. The fluorosilicon nitrile compounds are characterized by having a total of four substituents attached to a silicon atom, wherein one or two of the substituents are fluorine atoms, one or two of the substituents are cyanoalkyl groups, which are the same as or different from each other, and the remainder of the substituents, if any, are alkyl groups, which are the same as or different from each other. | 2017-10-05 |
20170283444 | STERICALLY HINDERED AMINE AND OXYALKYL AMINE LIGHT STABILIZERS - Compounds having hindered amine and oxyalkyl amine light stabilizers can mitigate the adverse effects of actinic radiation, such as visible and ultraviolet light, in particular on substrates such as glass or ceramic substrates. Polymers derived from such compounds. Nanoparticles, substrates, such as glass or ceramic substrates, or both nanoparticles and substrates, having such compounds affixed thereto. Articles containing at least one of such polymers, nanoparticles, substrates, or compounds. | 2017-10-05 |
20170283445 | Small Molecule Inhibitors Selective For Polo-Like Kinase Proteins - Disclosed are small molecule PLK inhibitors that can target the polo box domain (PBD). Inhibitors can have an atomic mass of about 1000 Da or less and a general structure of | 2017-10-05 |
20170283446 | SOLUBLE C5aR ANTAGONISTS - Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): | 2017-10-05 |
20170283447 | RUTHENIUM COMPLEXES AND THEIR USES AS CATALYSTS IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND RELATED REACTIONS - The present invention relates to novel Ruthenium complexes of formulae A1-A4 and their use, inter alia, for (1) dehydrogenative coupling of alcohols to esters; (2) hydrogenation of esters to alcohols (including hydrogenation of cyclic esters (lactones) or cyclic di-esters (di-lactones), or polyesters); (3) preparing amides from alcohols and amines—(including the preparation of polyamides (e.g., polypeptides) by reacting dialcohols and diamines and/or polymerization of amino alcohols and/or forming cyclic dipeptides from p-aminoalcohols; (4) hydrogenation of amides (including cyclic dipeptides, polypeptides and polyamides) to alcohols and amines; (5) hydrogenation of organic carbonates (including polycarbonates) to alcohols or hydrogenation of carbamates (including polycarbamates) or urea derivatives to alcohols and amines; (6) dehydrogenation of secondary alcohols to ketones; (7) amidation of esters (i.e., synthesis of amides from esters and amines); (8) acylation of alcohols using esters; (9) coupling of alcohols with water and a base to form carboxylic acids; and (10) preparation of amino acids or their salts by coupling of amino alcohols with water and a base. The present, invention further relates to the use of certain known Ruthenium complexes for the preparation of amino acids or their salts from amino alcohols. | 2017-10-05 |
20170283448 | METHOD FOR MANUFACTURING LIGNIN DEGRADATION PRODUCT - Provided is a method for producing a lignin degradation product that includes (1) a degradation step of degrading a raw material containing a plant biomass, in a mixed solvent of water and an aliphatic alcohol having from 4 to 10 carbon atoms, which separates into two phases at 0° C. or higher and 50° C. or lower, under the following conditions, and (2) after the degradation step, a liquid-liquid separation step of separating the lignin degradation product-containing organic phase from the solvent that has separated at the temperature for two-phase separation. The method produces a lignin degradation product at a high yield from lignin or a material containing lignin. Condition A: The concentration of the raw material to be in the mixed solvent is 1% by mass or more and 20% by mass or less. Condition B: The reaction temperature is 100° C. or higher and 350° C. or lower. Condition C: The reaction time is 0.1 hours or more and 10 hours or less. | 2017-10-05 |
20170283449 | STEVIA EXTRACTS | 2017-10-05 |
20170283450 | TRITERPENE SAPONINS, METHODS OF SYNTHESIS AND USES THEREOF - The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation. | 2017-10-05 |
20170283451 | DNA SEQUENCING BY SYNTHESIS USING RAMA AND IFRARED SPECTROSCOPY DETECTION - This invention provides a process of labeling a polynucleotide analogue to be detected by Raman and/or infrared spectroscopy detection. | 2017-10-05 |
20170283452 | N-ALKYL 2-(DISUBSTITUTED)ALKYNYLADENOSINE-5-URONAMIDES AS A2A AGONISTS - The present invention provides N-alkyl 2-(disubstituted)alkynyladenosine-5′-uronamides and derivatives thereof and pharmaceutical compositions containing the same that are selective agonists of A | 2017-10-05 |
20170283453 | COFACTOR ANALOGUES FOR METHYLTRANSFERASES - Cofactor analogues for methyltransferases are disclosed. The compounds are represented by formula (I) wherein R1 is COOH or COO—; X is an organic or inorganic anion carrying one or more negative charges; Y and Y′ are H, or an alkyl; R2 is NH | 2017-10-05 |
20170283454 | COMPOSITIONS COMPRISING CYCLIC PURINE DINUCLEOTIDES HAVING DEFINED STEREOCHEMISTRIES AND METHODS FOR THEIR PREPARATION AND USE - It is an object of the present invention to provide novel and highly active cyclic-di-nucleotide (CDN) immune stimulators that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides that induce STING-dependent TBK1 activation, wherein the cyclic purine dinuclotides present in the composition are substantially pure Rp,Rp or Rp,Sp stereoisomers, and particularly substantially pure Rp,Rp, or RpSp CDN thiophosphate diastereomers. | 2017-10-05 |
20170283455 | STABLE TOPICAL PHAMACEUTICAL COMPOSITIONS OF HALOBETASOL PROPIONATE - The present invention provides a stable topical pharmaceutical composition of halobetasol propionate. The present invention discloses an impurity of compound of Formula II and its process of preparation. It also relates to a method of evaluating stability of a topical pharmaceutical composition of halobetasol propionate. | 2017-10-05 |
20170283456 | PROTEIN LABELING WITH CYANOBENZOTHIAZOLE CONJUGATES - The invention provides compounds and methods for site-specifically labeling proteins with cyanobenzothiazole derivatives of formula I. For example, the invention provides methods for labeling the N-terminus of a protein that terminates with a cysteine residue. The invention also provides methods for isolating an N-terminally labeled protein and methods for detecting an N-terminally labeled protein. | 2017-10-05 |
20170283457 | USE OF INHIBITORY PEPTIDES FOR THE TREATMENT OF INFLAMMATORY DISEASES - An isolated peptide is disclosed which comprises an amino acid sequence being at least 80% homologous to the sequence as set forth in SEQ ID NO: 1 (PERYQNLSPV), the isolated peptide comprising a nuclear targeting activity, the peptide being no longer than 20 amino acids. | 2017-10-05 |
20170283458 | COLLAGEN-BINDING SYNTHETIC PEPTIDOGLYCANS FOR WOUND HEALING - Methods and compositions for promoting wound healing in a patient by administering a collagen-binding synthetic peptidoglycan to the patient are described. Additionally, methods and compositions are described for decreasing scar formation in a patient by administering a collagen-binding synthetic peptidoglycan to the patient. | 2017-10-05 |
20170283459 | PEPTIDE INHIBITORS OF CALCIUM OXALATE MONOHYDRATE CRYSTALLIZATION AND USES THEREOF - In an embodiment, the present disclosure pertains to a composition for inhibiting calcium oxalate monohydrate crystal growth comprising at least one isolated polypeptide comprising a plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal; and a plurality of amino acids spacers, wherein the amino acid spacers are arranged in varying sequences between the plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal. In some embodiments, the present disclosure related to a method of controlling calcium oxalate monohydrate crystal growth in a subject in need thereof comprising administering to the subject therapeutically effective amount of the calcium oxalate monohydrate inhibiting polypeptide. In some embodiments, the present disclosure relates to a method of identifying calcium oxalate monohydrate inhibiting peptides. Such a method may comprise designing a peptide library of potential calcium oxalate inhibiting peptides; screening the peptide library for high efficacy inhibitor peptides for inhibition of calcium oxalate monohydrate crystallization; and conducting molecular characterization of the high efficacy inhibitor to determine specificity. | 2017-10-05 |
20170283460 | Immune System Modulation for Prophylaxis and Treatment of Diseases and Disorders - The invention is directed to biological response modifiers (BRM) which may contain one or more compounds, and to methods for enhancement of an immune system with BRMs of the invention including augmenting a specific immune response either prophylactically or for treatment, as an adjuvant or vaccine when coupled with a pathogenic antigen, and for boosting an immune system generally. The invention is also directed to the reduction of an unrestrained or improper inflammatory response and/or an immune response such as to treat or prevent autoimmune diseases and disorders, and associated symptoms. Further, the invention is directed to the manufacture of BRM compounds comprising isolated serum from a mammal, and subjecting that serum to tangential flow chromatography and molecular weight cut-off dialysis to obtain one or more purified BRM compounds suitable for administration to a patient in need. | 2017-10-05 |
20170283461 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS - In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ | 2017-10-05 |
20170283462 | IMMUNOMODULATORS - The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases. | 2017-10-05 |
20170283463 | IMMUNOMODULATORS - The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases. | 2017-10-05 |
20170283464 | Crystalline And Amorphous Forms Of A Beta-Arrestin Effector - The present disclosure provides novel crystalline forms of a compound that acts as a β-arrestin effector, processes for preparing novel crystalline and amorphous forms of a compound that acts as a β-arrestin effector and uses thereof. | 2017-10-05 |
20170283465 | NOVEL ANGIOTENSIN TYPE 2 (AT2) RECEPTOR AGONISTS AND USES THEREOF - The invention relates to novel pharmaceutically-useful peptides, in particular cyclic peptides that are agonists of the AngII type 2 receptor (AT2 receptor). The invention further relates to the use of such peptides as medicaments, to pharmaceutical compositions containing them, and to their production. | 2017-10-05 |
20170283466 | METHOD FOR PREPARING MULTIPLE ANTIGEN GLYCOPEPTIDE CARBOHYDRATE CONJUGATES - The present invention relates to a method for preparing carbohydrate T cell epitope conjugates of formula (I): M(T-B) | 2017-10-05 |
20170283467 | PROGRAMMABLE POLYPEPTIDE AND NUCLEIC ACID NANOPARTICLES - Provided herein are polypeptides that self-assemble into nanoparticles upon binding to nucleic acids. The nanoparticles find use, for example in the delivery of the nucleic acids into cells. | 2017-10-05 |
20170283468 | PEPTIDES FOR DIAGNOSIS AND TREATMENT OF CANCER - The present invention provides a method of peptide histochemical diagnosis to detect the peptide binding protein in the cancer tissue. This peptide binding specifically to tumor cells is linked to the dextran coated iron oxide nanoparticle. The peptide linked dextran coated iron oxide nanoparticle can be used to bind to the formalin-fixed and paraffin-embedded tumor surgical specimens, and the method of present invention can be used to evaluate the efficacy of peptide-targeted chemotherapy for treatment of cancer patients. | 2017-10-05 |
20170283469 | PROTEOLYTIC INACTIVATION OF SELECT PROTEINS IN BACTERIAL EXTRACTS FOR IMPROVED EXPRESSION - The present disclosure provides modified proteins that are capable of being cleaved by the protease OmpT1. The proteins can be modified in an exposed surface motif to incorporate OmpT1 cleavage sites. Also provided are nucleic acids encoding the modified proteins, bacterial cells that express the modified proteins, and cell free synthesis systems containing modified RF1. The disclosure further provides methods for reducing the deleterious activity of a modified protein in a cell free synthesis system by contacting the modified protein with OmpT1. Also provided are methods for reducing RF1 competition at an amber codon in the cell free synthesis system, and methods for expressing a protein in the cell free synthesis system. The modified proteins of the invention can be used to increase the yield of proteins having non-natural amino acids incorporated at an amber codon. | 2017-10-05 |
20170283470 | MUTANT CSGG PORES - The invention relates to mutant forms of the outer membrane located lipoprotein CsgG, in particular, modifications at one or more of positions Tyr51; Asn55; and Phe56. The invention also relates to analyte detection and characterisation using said mutant CsgG. | 2017-10-05 |
20170283471 | MODIFIED MICROBIAL TOXIN RECEPTOR FOR DELIVERING AGENTS INTO CELLS - We described a novel system of targeted cell therapy with a protein toxin, such as anthrax toxin, that has been modified to re-direct it to a desired cell target instead of its natural cell target. The system can be used for, e.g., targeted killing of undesired cells in a population of cells, such as cancer or overly active immune system cells. | 2017-10-05 |
20170283472 | COMPOSITIONS COMPRISING RECOMBINANT BACILLUS CELLS AND ANOTHER BIOLOGICAL CONTROL AGENT - The present invention relates to a composition comprising a) recombinant exosporium-producing | 2017-10-05 |
20170283473 | GENETICALLY MODIFIED HIGHER PLANTS WITH INCREASED PHOTOSYNTHESIS AND/OR BIOMASS PRODUCTION, METHODS AND USES THEREOF - The technology provided herein generally relates relates to genetically modified higher plants, for example C3 and C4 plants, and subsequent generations thereof, comprising stable and/or transient expression of at least one gene-product (e.g. mRNA or protein) of the “ | 2017-10-05 |
20170283474 | PRODUCTION OF PROTEINS AND POLYPEPTIDES - A method of producing a desired non-spidroin protein or polypeptide is comprising the steps of expressing in a suitable host a fusion protein, obtaining a mixture containing the fusion protein, and optionally isolating the fusion protein. The fusion protein is comprising at least one solubility-enhancing moiety which is derived from the N-terminal (NT) fragment of a spider silk protein. It is further comprising at least one moiety which is a desired non-spidroin protein or polypeptide. Each solubility-enhancing moiety is linked directly or indirectly to the desired protein or polypeptide moiety. | 2017-10-05 |
20170283475 | CANCER VACCINE COMPOSITIONS AND METHODS OF USE THEREOF - The present application describes compositions that include an epitope of a peptide that elicits an immune response in a subject following administration. The compositions described herein include nucleic acids. The present application also describes compositions that include peptides. Also described herein are methods that include administering a composition comprising an epitope of a peptide to a subject in need thereof. | 2017-10-05 |
20170283476 | MYC NUCLEIC ACIDS AND USES THEREOF - Disclosed herein are molecules and pharmaceutical compositions that mediate RNA interference against MYC. Also described herein include methods for treating a disease or disorder that comprises a molecule or a pharmaceutical composition that mediate RNA interference against MYC. | 2017-10-05 |
20170283477 | ANIMAL MODEL OF LONGEVITY AND RELATED METHODS FOR INCREASING LONGEVITY AND INHIBITING TUMORIGENESIS - The present invention includes a genetically-modified non-human animal model of longevity and increased health span, which is associated with reduced tumorigenesis and tumor metastasis, as well as related methods for increasing longevity and health span, reducing tumorigenesis and tumor metastasis, and identifying active agents that confer increased longevity or health span, or reduced tumorigenesis or tumor metastasis. | 2017-10-05 |
20170283478 | PROCESS FOR PREPARATION OF LIRAGLUTIDE - The present application relates to improved processes for the preparation of Liraglutide. | 2017-10-05 |
20170283479 | LIPIDATED AMIDE-BASED INSULIN PRODRUGS - Prodrug formulations of insulin and insulin analogs are provided wherein the insulin peptide has been modified by an amide bond linkage of a dipeptide prodrug element. The prodrugs disclosed herein have extended half-lives and are converted to the active form at physiological conditions through a non-enzymatic reaction driven by chemical instability. | 2017-10-05 |
20170283480 | PEPTIDES HAVING REDUCED TOXICITY THAT STIMULATE CHOLESTEROL EFFLUX - The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimers Disease or frontotemporal dementia. | 2017-10-05 |
20170283481 | Engineered Invariant Natural Killer T (iNKT) Cells and Methods of Making and Using Thereof - Disclosed are invariant natural killer T (iNKT) cells engineered using hematopoietic stem and progenitor cells (HSPCs) and methods of making and using thereof. Specifically, the engineered cells iNKT are genetically modified to contain at least one exogenous invariant natural killer T cell receptor (iNKT TCR) nucleic acid molecule. Further disclosed are iNKT TCR nucleotide sequences and codon optimized sequences for expression. | 2017-10-05 |
20170283482 | Chimeric Receptors with 4-1BB Stimulatory Signaling Domain - The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 4-1BB signaling domain. Embodiments of the invention relate to polynucleotides that encode the receptor, vectors and host cells encoding a chimeric receptor, particularly including T cells and natural killer (NK) cells and methods of use. | 2017-10-05 |
20170283483 | METHODS OF MODIFYING ANTIBODIES FOR PURIFICATION OF BISPECIFIC ANTIBODIES - The present inventors devised methods for efficiently purifying bispecific antibodies using a chromatography column based on the difference in isoelectric points between the H chains of two types of antibodies, wherein the difference is introduced by modifying the amino acids present on the surface of the antibody variable regions of two types of antibodies that constitute a bispecific antibody. Furthermore, the inventors devised methods for efficiently purifying bispecific antibodies using a chromatography column by linking respective antigen binding sites (heavy chain variable regions) to the antibody constant regions having different isoelectric points, and then coexpressing these antibodies. | 2017-10-05 |
20170283484 | ANTI-HEPATITIS C ANTIBODIES AND ANTIGEN BINDING FRAGMENTS THEREOF - The invention provides an antibody or antigen binding fragment thereof capable of binding to the antigen binding pocket of the AP33 antibody, wherein said antibody or antigen binding fragment thereof comprises VL CDR1 (L1), VL CDR2 (L2), and VL CDR | 2017-10-05 |
20170283485 | ANTIBODY CAPABLE OF BINDING TO INFLUENZA VIRUS - The present invention provides a novel antibody capable of binding influenza virus. The antibody directed to the present invention consists of an amino acid sequence, wherein said amino acid sequence consists of, in an N- to C-direction, the following structural domains: | 2017-10-05 |
20170283486 | STABLE IMMUNOGEN BASED ON INNER DOMAIN OF HIV-1 GP120 FOR INDUCING IMMUNITY AGAINST HIV - Stable immunogens comprising portions of the inner domain (ID) of the Human Immunodeficiency Virus (HIV-1) gp120 protein are provided. These ID immunogens selectively present the gp120 C1/C2 region in its CD4-bound state within a minimal structure. These ID immunogens can be used to vaccinate subjects against infection with HIV, the causative agent of Acquired Immunodeficiency Syndrome (AIDS). The immunogens can also be used as targets in screening to identify small molecule or peptide inhibitors that block HIV-1 viral entry and attachment steps, and as probes for identifying gp120 C1/C2 region-specific antibodies. | 2017-10-05 |
20170283487 | IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS - The present specification discloses SNAP-25 compositions, methods of making α-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P | 2017-10-05 |
20170283488 | ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS - Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor. | 2017-10-05 |
20170283489 | Chimeric Antigen Receptor Specific for SSEA4 Antigen - The present invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain specific for SSEA4, a population of engineered cells expressing said CARs, and a pharmaceutical composition comprising said genetically modified cells expressing said CARs. The pharmaceutical composition may be for use of the treatment of cancer in a subject suffering from cancer, wherein at least a subpopulation of the cancerous cells of said cancer expresses SSEA4. | 2017-10-05 |
20170283490 | NANOBODIES SUITABLE FOR NEURON REGENERATION THERAPY - The invention is in the domain of delivery of molecules to brain cells across the blood-brain barrier. The invention relates to a novel polypeptide-based carrier that allows the efficient delivery of an effector peptide, to neuron cells across the blood-brain barrier, and to methods for the production and testing of such carrier, including a model for testing the capacity of such molecule to cross the blood-brain barrier and/or the toxicity of molecules on the blood brain barrier and/or the capacity of molecules that have crossed to target human brain cells (e/g. neurons, astrocytes and microglial cells). | 2017-10-05 |
20170283491 | METHOD OF PROVIDING DISEASE-SPECIFIC BINDING MOLECULES AND TARGETS - Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described. | 2017-10-05 |
20170283492 | Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods - The invention provides a polypeptide containing at least one IgG Fc region, wherein said at least one IgG Fc region is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by a α 2,6 linkage, and wherein said polypeptide having a higher anti-inflammatory activity as compared to an unpurified antibody. | 2017-10-05 |
20170283493 | METHODS FOR ENHANCING PERMEABILITY TO BLOOD-BRAIN BARRIER, AND USES THEREOF - Disclosed herein is a method of facilitating the delivery of an agent across blood-brain barrier (BBB) of a subject. The method includes administering to the subject in sequence or concomitantly, an effective amount of a growth factor selected from the group consisting of, vascular endothelial growth factor (VEGF), insulin-like growth factor I (IGF-1), IGF-II, a portion thereof and a combination thereof; and an agent that is any of a therapeutic agent or an imaging agent. The administered amount of the growth factor is capable of transiently increasing BBB permeability of the subject and thereby allowing the agent to be delivered across BBB. Also disclosed herein is a method of treating a subject suffering from a brain tumor, a brain stroke, a neuropsychiatric disorder and/or a neurodegenerative disease. | 2017-10-05 |
20170283494 | HUMAN ANTI-IL-33 NEUTRALIZING MONOCLONAL ANTIBODY - An antibody has an antagonistic effect against IL-33. In particular an isolated human anti-IL-33 neutralizing monoclonal antibody has framework regions with amino acid sequences from a germline, including combinations and fragments of such sequences. The epitopes for a plurality of anti-IL-33 monoclonal antibodies were identified, human anti-IL-33 neutralizing monoclonal antibodies were obtained, and the complementarity-determining regions that achieve high binding ability to IL-33 was specified by introducing mutations in the complementarity-determining regions. The identified complementarity-determining regions were used to produce the foregoing human anti-IL-33 neutralizing monoclonal antibodies having framework regions. | 2017-10-05 |
20170283495 | ANTI-HEPCIDIN ANTIBODIES AND USES THEREOF - The present application relates to antibodies that specifically bind to hepcidin and methods of using the antibodies. Another aspect relates to antibodies which bind hepcidin and regulate iron homeostasis. Another aspect relates to the use of humanized antibodies which bind hepcidin for the treatment of a disease or condition associated with hepcidin. | 2017-10-05 |
20170283496 | OLIGONUCLEOTIDES FOR REDUCTION OF PD-L1 EXPRESSION - The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide. | 2017-10-05 |
20170283497 | ROR1 (NTRKR1) SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY - The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a ROR1 monoclonal antibody, conferring specific immunity against ROR1 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia, and for solid tumors such as breast, colon, lung, and kidney tumors | 2017-10-05 |
20170283498 | THERAPEUTIC CD47 ANTIBODIES - Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of, CD47, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents that are toxic to susceptible cancer cells, promoting their phagocytic uptake and clearance, or directly killing such cells. | 2017-10-05 |
20170283499 | ANTIBODY WHICH IS DIRECTED AGAINST GALECTIN-9 AND IS AN INHIBITOR OF THE SUPPRESSOR ACTIVITY OF REGULATORY T LYMPHOCYTES - The invention relates to an antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes, and also to the use of this antibody for the treatment of diseases associated with the suppressor activity of regulatory T lymphocytes, in particular the treatment of cancer. | 2017-10-05 |
20170283500 | CHIMERIC RECEPTORS AND METHODS OF USE THEREOF - Antigen binding molecules, chimeric receptors, and engineered immune cells are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the antigen binding molecules and engineered immune cells. | 2017-10-05 |
20170283501 | Antigen Binding Proteins that Bind c-Met - There is disclosed compositions and methods relating to or derived from anti-c-Met antibodies. More specifically, there is disclosed fully human antibodies that bind c-Met, c-Met-binding fragments and derivatives of such antibodies, and c-Met-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having c-Met related disorders or conditions, including various inflammatory disorders and various cancers. | 2017-10-05 |
20170283502 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING INFLAMMATION - The present invention provides novel compounds compositions and methods for (i) treating or preventing inflammation; and (ii) preventing or reducing hyperactivation of innate immune response, by inhibiting NRP1-dependent cell-signaling. Also provided are compounds, composition, and methods of specifically inhibiting SEMA3A-mediated cell signaling. | 2017-10-05 |
20170283503 | COMPOSITIONS COMPRISING RANK/RANKL ANTAGONISTS AND RELATED COMPOUNDS FOR TREATING PAIN - Disclosed herein are methods of treating pain using RANK/RANKL antagonists. | 2017-10-05 |
20170283504 | BCMA BINDING MOLECULES AND METHODS OF USE THEREOF - The invention provides antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs), and engineered T cell receptors, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma. | 2017-10-05 |
20170283505 | PRODUCTION OF PROTEINS IN GLUTAMINE-FREE CELL CULTURE MEDIA - The present invention relates generally to glutamine-free cell culture media supplemented with asparagine. The invention further concerns the production of recombinant proteins, such as antibodies, in asparagine-supplemented glutamine-free mammalian cell culture. | 2017-10-05 |
20170283506 | LUNG CANCER DIFFERENTIAL MARKER - An object of the present invention is to develop and provide a lung cancer differential marker with which lung cancer can be diagnosed conveniently and highly sensitively without depending only on increase or decrease in protein expression level between cancer patients and healthy persons. Another object of the present invention is to develop and provide a glycan marker capable of distinguishing histological types of lung cancer. Of serum glycoproteins, glycopeptide and glycoprotein groups whose glycan structures were altered specifically in lung cancer cell culture supernatants were identified, and they are provided as lung cancer differential markers. | 2017-10-05 |
20170283507 | CAR-EXPRESSING NK-92 CELLS AS CELL THERAPEUTIC AGENTS - The present invention relates to an ErbB2-specific NK-92 cell or cell line containing a lentiviral vector encoding a chimeric antigen receptor and preferably two vector integration loci in its cellular genome. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line in the prevention and/or treatment of cancer, preferably ErbB2-expressing cancers. The present invention further relates to the use of the ErbB2-specific NK-92 cell or cell line as targeted cell therapeutic agent and/or for adoptive cancer immunotherapy. The present invention further relates to a method for generating an ErbB2-specific NK-92 cell or cell line as well as to a method for identifying an ErbB2-specific NK-92 cell or cell line and to the ErbB2-specific NK-92 cell or cell line obtained or identified by the methods as well as their uses. | 2017-10-05 |
20170283508 | Methods for Inhibiting Angiogenesis in a Subject in Need Thereof - In one aspect, the present invention provides methods for preventing, treating, reverting and/or delaying angiogenesis in a mammalian subject suffering from, or at risk for developing, an angiogenesis-dependent disease or condition, comprising administering to the subject an amount of a MASP-2 inhibitory agent effective to inhibit angiogenesis. In some embodiments of these aspects of the invention, the MASP-2 inhibitory agent is a MASP-2 antibody or fragment thereof. | 2017-10-05 |
20170283509 | BLOCKING MONOCLONAL ANTIBODIES TO AGR2 AND ITS RECEPTOR C4.4A - Provided herein are monoclonal antibodies that recognize, bind to, and block interactions of other molecules with AGR2 and C4.4A. Also provided herein are methods of using said antibodies to treat cancer. | 2017-10-05 |
20170283510 | MODIFIED J-CHAIN - The present invention concerns modified recombinant J-chain polypeptides, binding molecules, such as antibodies comprising the same, and their uses. | 2017-10-05 |
20170283511 | BISPECIFIC ANTIBODIES THAT NEUTRALIZE BOTH TNF-ALPHA AND IL-6: NOVEL THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE - The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one anti-TNF-α antibody or antigen-binding fragment thereof and at least one anti-IL-6 antibody or antigen-binding fragment thereof. Preferably, the bispecific antibody is in the form of a DNL® complex. The anti-TNF-α or anti-IL-6 antibodies may comprise specific CDR sequences disclosed herein. The compositions and methods are of use to treat autoimmune disease, immune system dysfunction or inflammatory disease, as disclosed herein. | 2017-10-05 |
20170283512 | CELLULOSE SUSPENSION, METHOD FOR THE PRODUCTION AND USE THEREOF - The present invention relates to a phase-stable suspension of cellulose II in water, having a high water retention capacity and a cellulose concentration between 0.1 and 5.0% by weight, a method of its preparation, and its use. | 2017-10-05 |
20170283513 | METHOD FOR PRODUCING WATER-SOLUBLE NONIONIC CELLULOSE ETHER POWDER HAVING HIGH BULK DENSITY - Provided is a method of stably producing a water-soluble nonionic cellulose ether powder having a high bulk density at low cost by adding a minimum amount of water. More specifically provided is a method for producing a water-soluble nonionic cellulose ether powder, comprising the steps of: reacting alkali cellulose with an etherifying agent to obtain a reaction product; washing and draining the reaction product to obtain a water-soluble nonionic cellulose ether; mixing the water-soluble nonionic cellulose ether with such an amount of water of 70° C. or higher as to make a water content of the water-soluble nonionic cellulose ether become 55 to 90% by weight to obtain a water-containing water-soluble nonionic cellulose ether having a water content of 55 to 90% by weight; cooling the water-containing water-soluble nonionic cellulose ether; and drying and pulverizing the cooled water-containing water-soluble nonionic cellulose ether. | 2017-10-05 |
20170283514 | HYPROMELLOSE ACETATE SUCCINATE POWDER EXCELLENT IN DISSOLVED STATE AND PRODUCTION METHOD THEREOF, AND PRODUCTION METHODS FOR COMPOSITION FOR SOLID DISPERSION, COATING COMPOSITION, DRUG-CONTAINING PARTICLE, AND SOLID PREPARATION - Provided are HPMCAS powder having high solubility when dissolved in a solvent and being capable of suppressing generation of undissolved materials; and a method for producing the powder. More specifically, provided is hypromellose acetate succinate powder having an average ratio of L to D of from 2.0 to 3.0, wherein L and D mean maximum and minimum diameters of each particle, respectively. Also provided is a method for producing a hypromellose acetate succinate, comprising the steps of: dissolving hypromellose powder in a solvent, esterifying the dissolved hypromellose with succinic anhydride and acetic anhydride in the presence of a catalyst to obtain a reaction mixture, and mixing the reaction mixture with water to precipitate hypromellose acetate succinate, wherein the reaction mixture just before being mixed with the water has a viscosity of from 100 to 200 Pa·s. | 2017-10-05 |
20170283515 | Methods of Preparing Hemicellulose Compositions - Multi-extraction methods for preparing hemicellulose compositions are provided. Depressant compositions comprising hemicellulose compositions are also provided herein. Also disclosed are processes for enriching a desired mineral from an ore comprising the desired mineral, wherein the process comprises carrying out a flotation process in the presence of one or more collecting agents and a depressant composition comprising hemicellulose. | 2017-10-05 |
20170283516 | PROCESSES FOR PREPARING AMINOSILANE FUNCTIONALIZED POLYMERS - Metallated aminosilane compounds for use as functional initiators in anionic polymerizations and processes for producing an aminosilane-functionalized polymer using the metallated aminosilane compounds to initiate anionic polymerization of at least one type of anionically polymerizable monomer. Preferred use of the metallated aminosilane compounds results in rubber compositions for use in tires comprising an aminosilane functionalized polymer. | 2017-10-05 |
20170283517 | SULFUR-CONTAINING ORGANIC-INORGANIC HYBRID GEL COMPOSITIONS AND AEROGELS - Methods and materials are described for preparing organic-inorganic hybrid gel compositions where a sulfur-containing cross-linking agent covalently links the organic and inorganic components. The gel compositions are further dried to provide porous gel compositions and aerogels. The mechanical and thermal properties of the dried gel compositions are also disclosed. | 2017-10-05 |
20170283518 | Rubber Composition for Tires and Pneumatic Tire - A rubber composition for tires of the present technology contains a diene rubber, silica, and a predetermined alkyltrialkoxysilane; the diene rubber containing a butadiene rubber and a particular conjugated diene rubber, a content of the butadiene rubber in the diene rubber being 20 mass % or greater and a content of the particular conjugated diene rubber in the diene rubber being from 30 to 80 mass %; an average glass transition temperature of the diene rubber being from −65 to −45° C.; the particular conjugated diene rubber being a conjugated diene rubber produced by a particular production method and having predetermined ranges of aromatic vinyl unit content, vinyl bond content, and weight average molecular weight. | 2017-10-05 |